Innoviva Ownership
| INVA Stock | USD 18.90 0.01 0.05% |
Shares in Circulation | First Issued 2004-06-30 | Previous Quarter 62.5 M | Current Value 63 M | Avarage Shares Outstanding 88.1 M | Quarterly Volatility 24.8 M |
Innoviva |
Innoviva Stock Ownership Analysis
About 99.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 1.77. Some equities with similar Price to Book (P/B) outperform the market in the long run. Innoviva has Price/Earnings To Growth (PEG) ratio of 0.24. The entity last dividend was issued on the 8th of September 2015. The firm had 1241:1000 split on the 3rd of June 2014. Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California. Innoviva operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 5 people. To learn more about Innoviva call the company at 650 238 9600 or check out https://www.inva.com.Besides selling stocks to institutional investors, Innoviva also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Innoviva's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Innoviva's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Innoviva Quarterly Liabilities And Stockholders Equity |
|
Innoviva Insider Trades History
Only 1.06% of Innoviva are currently held by insiders. Unlike Innoviva's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Innoviva's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Innoviva's insider trades
Innoviva Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Innoviva is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Innoviva backward and forwards among themselves. Innoviva's institutional investor refers to the entity that pools money to purchase Innoviva's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-09-30 | 1.4 M | Goldman Sachs Group Inc | 2024-09-30 | 1.2 M | Bank Of America Corp | 2024-09-30 | 1.1 M | Arrowstreet Capital Limited Partnership | 2024-09-30 | 1.1 M | American Century Companies Inc | 2024-09-30 | 1.1 M | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 1 M | Deutsche Bank Ag | 2024-09-30 | 848.2 K | Charles Schwab Investment Management Inc | 2024-09-30 | 732.3 K | D. E. Shaw & Co Lp | 2024-09-30 | 658.1 K | Blackrock Inc | 2024-09-30 | 9.4 M | Sarissa Capital Management Lp | 2024-09-30 | 7.3 M |
Innoviva Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Innoviva insiders, such as employees or executives, is commonly permitted as long as it does not rely on Innoviva's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Innoviva insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Innoviva Outstanding Bonds
Innoviva issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Innoviva uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Innoviva bonds can be classified according to their maturity, which is the date when Innoviva has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US45782BAD64 Corp BondUS45782BAD64 | View | |
| Installed Building Products Corp BondUS45780RAA95 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Innoviva Corporate Filings
| 27th of January 2025 Other Reports | ViewVerify | |
F4 | 22nd of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 14th of November 2024 An amendment to the original Schedule 13D filing | ViewVerify |
8K | 6th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Innoviva offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Innoviva's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Innoviva Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Innoviva Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Innoviva. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For information on how to trade Innoviva Stock refer to our How to Trade Innoviva Stock guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Innoviva. If investors know Innoviva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Innoviva listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.98) | Earnings Share 0.8 | Revenue Per Share | Quarterly Revenue Growth 0.331 | Return On Assets |
The market value of Innoviva is measured differently than its book value, which is the value of Innoviva that is recorded on the company's balance sheet. Investors also form their own opinion of Innoviva's value that differs from its market value or its book value, called intrinsic value, which is Innoviva's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Innoviva's market value can be influenced by many factors that don't directly affect Innoviva's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Innoviva's value and its price as these two are different measures arrived at by different means. Investors typically determine if Innoviva is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Innoviva's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.